News articles about Kadmon (NYSE:KDMN) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kadmon earned a news impact score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.7447537510859 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the headlines that may have effected Accern Sentiment’s rankings:

Kadmon (NYSE KDMN) opened at $3.63 on Friday. The firm has a market capitalization of $285.47, a price-to-earnings ratio of -2.07 and a beta of 5.59. Kadmon has a 52-week low of $2.05 and a 52-week high of $5.86.

A number of brokerages have weighed in on KDMN. Piper Jaffray Companies reissued a “positive” rating and set a $9.00 price target (up previously from $7.00) on shares of Kadmon in a research note on Tuesday, February 13th. Zacks Investment Research lowered Kadmon from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Jefferies Group increased their target price on Kadmon to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, February 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Kadmon in a research report on Friday, December 15th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $10.21.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at

About Kadmon

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Insider Buying and Selling by Quarter for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with's FREE daily email newsletter.